Cre/loxP system オ モチイタ HER2/neu ハツゲン サイボウ ニ タイスル トクイテキ カツ コウリツテキ イデンシ ドウニュウ システム ノ カイハツ
| Autor: | Nodagashira, Tatsuya, Odagiri, Hiroki, Ikenaga, Shojiro-Kazunori, Maruyama, Masateru, Sato, Toshiyuki, Hakamada, Kenichi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | 弘前医学. 61(1):26-34 |
| ISSN: | 0439-1721 |
| Popis: | Tissue-specifi c promoter has been used for cancer-specifi c suicide gene therapy, but its transcriptional activity is relatively low. For more effi cient gene therapy of HER2-expressing tumor, a double adenovirus infection system was established, in which a ‘regulator’ vector carried Cre gene under the control of HER2 promoter and ‘target’ vectors carried target genes activated by Cre. We constructed a Cre recombinase expression vector, AxHER2Cre, for the ‘regulator’ vector. By the combination of this vector and AxCALNLZ, β-D-galactosidase was induced in 90% and 70% of MKN7 and MDA-MB-453, HER2‒overexpressing cell lines, but only about 20% and 10% of MKN28 and MCF7, low HER2-expressing cell lines. By the quantifi cation analysis, the β-galactosidase activities induced by this system were comparable to those by the combination of AxCANCre and AxCALNLZ. These results indicated that Cre/ loxP system under the regulation of HER2 promoter could induce effi cient gene expression, maintaining the HER2- expression specifi city. Breast cancer with HER2 overexpression is treated with trastuzumab. However, refractory or resitance of HER2 positive breast cancer against trastuzumab becomes a severe clinical problem, recently. This system seemed to be another therapeutic option. 弘前医学. 61(1), 2010, p.26-34 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|